Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Langer

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Seminars in Oncology|December 1, 1996
Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center NetworkC J Langer, M Millenson, P O'Dwyer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancerP J O'Dwyer, C J Langer, J Walczak, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approachC J Langer, N Rosenblum, M Hogan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2000
Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC)C J Langer, C A McAleer, C A Bonjo, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 1993
Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancerC J Langer, W J Curran, S M Keller, et al.
American Journal of Clinical Oncology|April 1, 1991
Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluationD S Ettinger, J D Bitran, R L Comis, et al.
British Journal of Cancer|June 3, 2015
Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxelC J Langer, V Hirsh, I Okamoto, et al.
The Cancer Journal From Scientific American|March 1, 1996
Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiationC J Langer, W J Curran, S M Keller, et al.
Head & Neck|July 15, 1998
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neckC J Langer, D Schaebler, E Sauter, et al.
Clinical Lung Cancer|December 9, 2003
Induction and concurrent paclitaxel/carboplatin every 3 weeks with thoracic radiotherapy in locally advanced non-small-cell lung cancer: an interim reportB Movsas, R S Hudes, J Schol, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Seminars in Oncology|December 1, 1996
Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center NetworkC J Langer, M Millenson, P O'Dwyer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancerP J O'Dwyer, C J Langer, J Walczak, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approachC J Langer, N Rosenblum, M Hogan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2000
Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC)C J Langer, C A McAleer, C A Bonjo, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 1993
Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancerC J Langer, W J Curran, S M Keller, et al.
American Journal of Clinical Oncology|April 1, 1991
Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluationD S Ettinger, J D Bitran, R L Comis, et al.
British Journal of Cancer|June 3, 2015
Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxelC J Langer, V Hirsh, I Okamoto, et al.
The Cancer Journal From Scientific American|March 1, 1996
Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiationC J Langer, W J Curran, S M Keller, et al.
Head & Neck|July 15, 1998
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neckC J Langer, D Schaebler, E Sauter, et al.
Clinical Lung Cancer|December 9, 2003
Induction and concurrent paclitaxel/carboplatin every 3 weeks with thoracic radiotherapy in locally advanced non-small-cell lung cancer: an interim reportB Movsas, R S Hudes, J Schol, et al.
Pageof 5